Table 4.
Disease response and PET SUV changes relative to baseline in each injected tumor after each dose of intratumoral HSV1716.
| Patient | Location of Injected Tumor | Day 14 CT/MRI | Day 14 PET | Day 28 CT/MRI | Day 28 PET | Time from Tx to Death (months) |
|---|---|---|---|---|---|---|
| HSV01 | Skull base | N/A | N/A | ND | ND | 1 |
| HSV02 | Left Lung metastasis | N/A | N/A | PD (2.6 cm to 3.3 cm) | SUV ↑ (8.3 to 9.9) | 2 |
| HSV03 | Paraspinal mass at L3 | N/A | N/A | PD (11.8 to 12.5 cm) | SUV ↑ (3.8 to 7.5) | 3 |
| HSV04 | Recurrent paraspinal mass at T8/9 | PD (2.5 to 4.7 cm) | SUV ↑ (13.6 to 19.6) | ND | ND | 1 |
| HSV05 | Left orbital metastasis | SD (3.4 to 3.4 cm) | SUV ↓ (5 to 3.8) | PD (4.8 cm) | ND | 2.5 |
| HSV06-I* | Recurrent retroperitoneal mass (posterior) | SD (11.6 to 11.1 cm) | SUV ↑ (minimal to 2.4) | SD (11 cm) | SUV ↑ (4.7) | 8 |
| HSV06-II | Retroperitoneal mass (anterior) | SD (11 to 10.5 cm) | SUV stable (4.7 to 4.8) | SD (10.3 cm) | SUV ↓ (2.52) | 7 |
| HSV07 | Recurrent Retroperitoneal mass | SD (10.4 to 9.7 cm) | SUV stable (4.96 to 4.9) | SD (10.6 cm) | ND | 25 |
| HSV08 | Right pleural metastasis | PD (5 to 6.3 cm) | SUV ↑↑ (3.2 to 10.1) | PD (7 cm) | SUV ↑ (4) | 7 |
| HSV09-A** | Right upper lobe metastasis | SD (3.3 to 3.4 cm) | SUV ↑ (4.1 to 4.9) | SD (3.3 cm) | SUV ↑ (4.6) | 6.5 |
| HSV09-B | Left upper lobe metastasis | SD (2.8 to 2.9 cm) | SUV stable (2.6 to 2.6) | SD (2.8 cm) | SUV | |
| HSV09-C | Right upper lobe metastasis | SD | SUV ↑ | SD | SUV stable |
N/A = not applicable; ND = not done; PD = progressive disease; SD = stable disease; SUV = standardized uptake value; cm = centimeters.
*
Patient HSV06 had 2 cycles of an injection of HSV1716 (HSV06-I and HSV06-II)
**
Patient HSV09 had 3 injected target lesions (A, B, C)